In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi

Medical Mycology

Volumn 43, Issue 3, 2005, Pages 281-284

  González, Gloria M ^a,b   Fothergill, Annette W ^b   Sutton, Deanna A ^b   Rinaldi, Michael G ^b,c   Loebenberg, David ^d  

^a Medicina UANL   (Mexico)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Fluconazole; Itraconazole; Posaconazole; Ravuconazole; Voriconazole

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; NEW DRUG; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG POTENCY; FUNGAL STRAIN; FUNGUS; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN DIFFERENCE;

ANTIBIOTICS, ANTIFUNGAL; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; PYRIMIDINES; SPECIES SPECIFICITY; THIAZOLES; TRIAZOLES;

AJELLOMYCES CAPSULATUS; AJELLOMYCES DERMATITIDIS; CLADOPHIALOPHORA CARRIONII; COCCIDIOIDES IMMITIS; FONSECAEA PEDROSOI; FUNGI; FUSARIUM; PAECILOMYCES LILACINUS; PSEUDALLESCHERIA BOYDII; SPOROTHRIX SCHENCKII;

EID: 20944445988     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780500088416     Document Type: Article

References (22)

1. Braddley JW, Stroud TP, Salzman D, et al. Invasive mold infections in allogenic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319-1324.
2. Ginter G, Petutschnig, Pierer G, et al. Atypical cutaneous pseudallescheriosis refractory to antifungal agents. Mycoses 1998; 42: 507-511.
3. Chan-Tack KM, Thio CL, Miller NS, Et al. Paecilomyces lilacinus fungemia in an adult bone marrow transplant recipient. Med Mycol 1999; 37: 57-60.
4. Patterson TF, Andriole VT, Zervos MJ, et al. The epidemiology of pseudallescheriasis complicating transplantation: nosocomial and community-acquired infection. Mycoses 1990; 33: 297-302.
5. Fish DG, Ampel NM, Galgiani JN, et al. Coccidioidomycosis during human immunodeficiency virus infection. Medicine 1990; 69: 384-391.
6. Johnson PC, Sarosi GA, Septimus EJ. Progressive disseminated histoplasmosis in patients with the acquired immune deficiency syndrome: a report of 12 cases and a literature review. Semin Resp Infect 1986; 1: 1-8.
7. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-329.
8. Hata K, Kimura J, Miki H, et al. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococosis. Antimicrob Agents Chemother 1996; 40: 2243-2247.
9. Hata K, Kimura J, Miki H, et al. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother 1996; 40: 2237-2242.
10. Galgiani JN, Lewis ML. In vitro studies of activities of the antifungal traizoles SCH 56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother 1997; 41: 180-183.
11. Oakley KL, Moore CB, Denning DW. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother 1997; 41: 1124-1126.
12. McGinnis MR, Pasarell L, Sutton DA, et al. In vitro activity of voriconazole against selected fungi. Antimicrob Agents Chemother 1998; 36: 239-242.
13. McGinnis MR, Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. Antimicrob Agents Chemother 1998; 36: 2353-2355.
14. Clemons KV, Stevens DA. Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice. Antimicrob Agents Chemother 2001; 45: 3433-3436.
15. Rinaldi MG. Use of potato flakes agar in clinical mycology. J Clin Microbiol 1982; 15: 1159-1160.
16. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved standard. NCCLS document M38-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000.
17. Chapman SW, Rogers PD, Rinaldi MG, et al. Susceptibilities of clinical and laboratory isolates of Blastomyces dermatitidis to ketoconazole, itraconazole, and fluconazole. Antimicrob Agents Chemother 1998; 42: 978-980.
18. Johnson EM, Szekely A, Warnock DW. In vitro activity of voriconazole, itraconazole, and amphotericin B against filamentous fungi. J Antimicorb Chemother 1998; 42: 741-745.
19. Arikan S, Lozano-Chiu M, Paetznick V, et al. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999; 37: 3946-3951.
20. González GM, Tijerina R, Najvar LK, et al. Activity of posaconazole against Pseudallescheria boydii: In vitro and in vivo assays. Antimicrob Agents Chemother 2003; 47: 1436-1438.
21. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001; 45: 2151-2153.
22. Minassian B, Huczko E, Washo T, et al. In vitro activity of ravuconazole against zygomycetes, Scedosporium and Fusarium isolates. Clin Microbiol Infect 2003; 9: 1250-1252.